THE PRIORITY WINDOW CLOSED
The 60-day priority filing window under 21 C.F.R. § 1301.13(k) closed. Whether or not you filed, Schedule III changed the federal reality for every state-licensed medical marijuana operator, and it changed it differently depending on where you sit.
- If you filed during the priority window: you are now a DEA registrant, inside a federal compliance regime — security, recordkeeping, inventory, reporting, and DEA inspection. State-law compliance carries part of that load, not all of it. The gaps are your exposure.
- If you didn’t file: the pathway remains available in the standard queue (without priority processing or conditional operating authority), your medical channel is now a Schedule III substance federally, your § 280E position may have changed, and your federal status as an unregistered operator handling Schedule III product is a question you should not leave unanswered.
- Either way, the landscape is moving weekly — IRS transition guidance, rescheduling proceedings, DOJ enforcement posture, and the treatment of operators who didn’t file.
To find out where you stand: Call or text 916-572-6445, email Ryan@Kocotlaw.com, or schedule a consultation.
WHERE OPERATORS STAND NOW
Schedule III landed differently on every operator. Find your seat:
- Medical-only, registered. You’re under DEA oversight now. The question is inspection-readiness.
- Medical-only, didn’t register. Your posture shifted anyway. The § 280E opportunity and the unregistered-status question are both on your plate.
- Dual channel (medical + adult-use). Your medical side moved to Schedule III; your adult-use side is still Schedule I. The separation between them (operational, financial, inventory, banking) is now load-bearing.
- Adult-use only. Nothing changed for you today, but the medical pathway is the template for what could come.
WHAT § 1301.13(k) DOES
On April 28, 2026, the Acting Attorney General published AG Order No. 6754-2026, 91 Fed. Reg. 22714, rescheduling FDA-approved marijuana drug products and marijuana subject to a state medical marijuana license from Schedule I to Schedule III of the Controlled Substances Act. The same order created an expedited federal registration pathway at 21 C.F.R. § 1301.13(k) for state-licensed medical marijuana operators.
The pathway provides five things that didn’t exist before:
- A federal registration category that matches state-licensed medical activity. Under § 1301.13(k)(1), state-licensed operators can register as manufacturers, distributors, or dispensers. A single entity may hold multiple categories.
- State licenses as conclusive evidence of state authorization. Under § 1301.13(k)(2), a current state medical marijuana license is “conclusive evidence” that the applicant is authorized under state law to engage in the licensed activity.
- State recordkeeping accepted to the maximum extent permissible. Under § 1301.13(k)(4), state-required reports, records, and forms are accepted in lieu of federal versions wherever federal statutory and treaty obligations permit. METRC and equivalent state track-and-trace systems may satisfy or support many inventory and recordkeeping requirements, but operators should not assume state records cover every federal obligation without a gap review.
- Conditional operating authority during pendency — for priority-window filers. Under § 1301.13(k)(7), applicants who filed within the 60-day window may engage in the manufacture, distribution, and/or dispensing of marijuana for medical purposes in conformity with a state-issued license while the application is pending. This authority belongs to window filers; applications filed after June 27 do not carry it.
The flipside: registration ties federal authorization to state authorization. Under § 1301.13(k)(3), DEA registration automatically suspends when the state license is suspended, revoked, or expires. Federal scope cannot exceed state scope.
FILING AFTER THE WINDOW: WHAT CHANGES
The registration pathway did not close entirely; the priority did. Standard-queue applications remain available for every registration category. What’s different:
- No conditional operating authority during pendency. Post-window applicants should plan for activity exposure during the review period; that planning is part of the engagement, not an afterthought.
- No priority processing. Post-window applicants should plan for longer and less predictable review timelines.
- The eligibility, records, public-interest, and Article 23 work is unchanged — and doing it right the first time matters more when there’s no priority treatment to absorb a bounce-back.
WHO NEEDS A DEA REGISTRATION ATTORNEY
State-licensed medical marijuana operators pursuing federal DEA registration under § 1301.13(k):
- Dispensaries and retailers. State-licensed medical marijuana retailers register federally to dispense Schedule III marijuana products under § 1301.13(k)(1)(iii).
- Cultivators. Cultivation operations register as manufacturers under § 1301.13(k)(1)(i), with cultivation-area designation required under § 1301.13(k)(6)(iii) and Article 23 compliance under § 1301.13(k)(6)(i)-(ii).
- Manufacturers. Extraction, infusion, processing, packaging, and labeling operations register as manufacturers, with Article 23 obligations where applicable.
- Distributors. Operations moving marijuana between registered licensees register as distributors under § 1301.13(k)(1)(ii).
- Vertically integrated operators. Multiple registration categories may be required — manufacturer plus distributor plus dispenser — depending on which licensed functions handle medicinal product.
WHAT WE HANDLE IN A DEA REGISTRATION ENGAGEMENT
End-to-end, not just the form. A DEA registration application is a regulated filing under 21 C.F.R. Part 1301, and the form itself is the smallest part of the registration process. The work that determines whether the application is approved happens before submission.
- Eligibility analysis. Confirming registration category, identifying disqualifying criminal history or prior registration issues, and verifying state license alignment.
- Operational records review against 21 C.F.R. Part 1304 expectations. DEA expects supporting documentation — handling SOPs, inventory controls, employee screening procedures, and security systems consistent with federal standards. We review what you have, identify gaps, and prepare what’s missing before filing.
- Application preparation and filing. Form 224/225 preparation; supporting document compilation. Current DEA registration fees should be confirmed at the time of filing through the DEA portal or current fee schedule.
- Post-registration support. Registration renewals; amendments for location, ownership; inspection preparation; and Federal Status Change advisories when state-level changes affect federal registration.
WHAT THE Order DOES NOT DO
The April 2026 order is significant but limited:
- Does not legalize adult-use cannabis federally. Adult-use marijuana remains Schedule I. Operators with both M and A designations register only for the medical portion.
- Does not authorize interstate cannabis transfer. State-line movement requires separate compliance with 21 U.S.C. §§ 951-971 and the import/export permit requirements added to 21 C.F.R. § 1312.30(b)-(d).
- Does not automatically convert a state license into a DEA registration. Federal registration must be applied for, granted, and maintained.
- Does not protect activity outside the state license. Federal registration scope cannot exceed state license scope under § 1301.13(k)(3).
- Does not eliminate federal labeling requirements categorically. State-law labeling is accepted under § 1301.13(k)(8), but the warning required by 21 U.S.C. § 825(c) must appear where applicable.
- Does not deliver retroactive § 280E relief. The AG Order encourages Treasury to consider it. Treasury has not promulgated retrospective guidance.
REACH OUT AT (916) 572-6445 OR BOOK A FREE CONSULTATION
A short call typically identifies which situation you’re in, the issues to address first, and — if registration is on the table — the right categories and the documents to gather. No charge for the initial conversation.
Call or text 916-572-6445, email Ryan@Kocotlaw.com, or click the button to schedule a consultation.
FREQUENTLY ASKED QUESTIONS
I missed the priority window. What now?
The pathway remains available in the standard queue. You lose priority processing and the § 1301.13(k)(7) conditional operating authority during pendency, so post-window applicants should plan for activity exposure during the review period.
I didn’t register. What’s my exposure right now?
Your medical channel (if applicable) is now a Schedule III controlled substance federally, and handling a Schedule III substance generally requires a DEA registration. How the DEA will treat state-licensed operators who continue medical activity without registering remains unclear — enforcement priorities for that group have not been announced. That status question, your § 280E position, and your registration decision should be mapped deliberately, not guessed at.
Does DEA registration allow interstate cannabis shipments?
No. Interstate movement requires separate compliance with 21 U.S.C. §§ 951-971 and import/export permits under 21 C.F.R. § 1312.30(b)-(d). The April 2026 order added marijuana subject to a state medical marijuana license to the permit-required list. Registration under § 1301.13(k) does not include interstate transfer authority.
Does Schedule III apply to my adult-use operations?
No. Adult-use marijuana remains Schedule I. Operators with both medicinal and adult-use designations register only for the medical portion of the operation.
Will § 280E be retroactive?
The AG Order encourages Treasury to consider retrospective relief. Treasury has not promulgated retrospective guidance. Operators should not plan finances based on retrospective § 280E relief that has not been issued. Prospective 280E treatment may change for properly supported Schedule III medical activity, but operators should not assume blanket relief, retroactive relief, or simple allocation rules without tax guidance.